Francisco Partners Iv, L.P. Sells 471,975 Shares of GoodRx (NASDAQ:GDRX) Stock

GoodRx Holdings, Inc. (NASDAQ:GDRX) major shareholder Francisco Partners Iv, L.P. sold 471,975 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $3.53, for a total transaction of $1,666,071.75. Following the completion of the transaction, the insider directly owned 1,127,436 shares in the company, valued at $3,979,849.08. This represents a 29.51% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Francisco Partners Iv, L.P. also recently made the following trade(s):

• On Friday, August 21st, Francisco Partners Iv, L.P. sold 274,717 shares of GoodRx stock. The shares were sold at an average price of $3.50, for a total transaction of $961,509.50.
• On Thursday, August 20th, Francisco Partners Iv, L.P. sold 447,259 shares of GoodRx stock. The shares were sold at an average price of $3.52, for a total transaction of $1,574,351.68.

GoodRx Trading Down 3.1%

GoodRx stock traded down $0.11 during trading hours on Friday, hitting $3.45. The company had a trading volume of 1,746,243 shares, compared to its average volume of 1,833,117. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.38 and a current ratio of 1.38. The firm has a market cap of $1.18 billion, a P/E ratio of 86.27, a P/E/G ratio of 1.77 and a beta of 1.60. The company has a 50-day moving average price of $3.13 and a two-hundred day moving average price of $2.63. GoodRx Holdings, Inc. has a 1 year low of $1.77 and a 1 year high of $5.81.

GoodRx (NASDAQ:GDRX) last issued its earnings results on Wednesday, August 5th. The company reported $0.08 EPS for the quarter, hitting analysts’ consensus estimates of $0.08. GoodRx had a net margin of 2.07% and a return on equity of 7.22%. The business had revenue of $200.41 million for the quarter, compared to analyst estimates of $193.23 million. During the same period last year, the company posted $0.09 earnings per share. The company’s quarterly revenue was down 1.3% compared to the same quarter last year. On average, sell-side analysts anticipate that GoodRx Holdings, Inc. will post 0.16 earnings per share for the current year.

Hedge Funds Weigh In On GoodRx

A number of hedge funds and other institutional investors have recently modified their holdings of GDRX. AQR Capital Management LLC raised its stake in GoodRx by 124.4% in the first quarter. AQR Capital Management LLC now owns 282,320 shares of the company’s stock worth $1,245,000 after buying an additional 156,482 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of GoodRx by 7.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 783,378 shares of the company’s stock worth $3,455,000 after acquiring an additional 54,783 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of GoodRx during the 1st quarter worth $370,000. Creative Planning purchased a new stake in shares of GoodRx during the 2nd quarter worth $93,000. Finally, Cetera Investment Advisers bought a new stake in GoodRx during the second quarter valued at about $50,000. 63.77% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have commented on GDRX. TD Cowen raised their price objective on GoodRx from $4.00 to $5.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Citigroup upped their target price on GoodRx from $4.00 to $5.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. UBS Group increased their price target on GoodRx from $2.50 to $3.75 and gave the stock a “neutral” rating in a research report on Thursday, August 13th. Leerink Partners set a $5.00 price target on GoodRx in a research note on Thursday, August 6th. Finally, Barclays raised their price target on GoodRx from $3.00 to $4.00 and gave the company an “underweight” rating in a research note on Thursday. Four analysts have rated the stock with a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, GoodRx presently has an average rating of “Hold” and an average target price of $4.23.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.